Rwanda vs Thailand: Average cost of drugs for extensively drug-resistant tuberculosis
Rwanda
1,483 constant 2022 US$
in 2024
Thailand
1,561 constant 2022 US$
in 2024
Rwanda rank
35th
Thailand rank
32nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Rwanda
- Thailand
How they compare
Thailand currently reports 1,561 constant 2022 US$ against 1,483 constant 2022 US$ in Rwanda, a difference of 78 constant 2022 US$.
That makes Thailand's figure about 1.1 times Rwanda's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Rwanda ahead.
Rwanda ranks 35th and Thailand ranks 32nd of 56 countries.
Rwanda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Rwanda | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,647 constant 2022 US$ | 3,958 constant 2022 US$ | 1,688 constant 2022 US$ | Rwanda |
| 2020s | 3,070 constant 2022 US$ | 2,431 constant 2022 US$ | 639 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Rwanda or Thailand?
- Thailand, at 1,561 constant 2022 US$ against 1,483 constant 2022 US$ in Rwanda as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Rwanda and Thailand?
- 78 constant 2022 US$, with Thailand ahead.
- How many years of comparable data are there for Rwanda and Thailand?
- 8 years are reported by both, from 2017 to 2024.
- How do Rwanda and Thailand rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Rwanda ranks 35th and Thailand ranks 32nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.